1. Home
  2. SCYX vs LOAN Comparison

SCYX vs LOAN Comparison

Compare SCYX & LOAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$3.76

Market Cap

42.4M

Sector

Health Care

ML Signal

HOLD

Logo Manhattan Bridge Capital Inc

LOAN

Manhattan Bridge Capital Inc

HOLD

Current Price

$4.04

Market Cap

48.2M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCYX
LOAN
Founded
1999
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
42.4M
48.2M
IPO Year
2014
1999

Fundamental Metrics

Financial Performance
Metric
SCYX
LOAN
Price
$3.76
$4.04
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
78.7K
42.9K
Earning Date
05-06-2026
04-16-2026
Dividend Yield
N/A
10.06%
EPS Growth
61.36
N/A
EPS
N/A
0.21
Revenue
$257,000.00
$8,666,307.00
Revenue This Year
N/A
N/A
Revenue Next Year
$608.78
N/A
P/E Ratio
N/A
$37.27
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$4.10
52 Week High
$5.62
$5.79

Technical Indicators

Market Signals
Indicator
SCYX
LOAN
Relative Strength Index (RSI) 43.82 34.32
Support Level $3.68 N/A
Resistance Level $5.10 $4.52
Average True Range (ATR) 0.37 0.13
MACD -0.16 -0.04
Stochastic Oscillator 3.18 0.98

Price Performance

Historical Comparison
SCYX
LOAN

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

Share on Social Networks: